

PHARVARIS

\$300 Million
Follow-On Offering

LEERINK PARTNERS
Joint Bookrunner
December 2023

Leerink Partners Serves as Joint Bookrunner for Pharvaris' (Nasdaq: PHVS) \$300 Million Follow-On Offering

Key Transaction Highlights

- Underwritten confidentially marketed offering that priced on December 6th, concurrently with the announcement of positive top-line data from its CHAPTER-1 Phase 2 study for the treatment of hereditary angioedema (HAE).
- Well oversubscribed from both new and existing investors
- Deal priced at \$24.00 per share and \$23.99 per pre-funded warrant, representing a 32% premium to the 5-day VWAP prior to pricing.
- General Atlantic and other new and existing institutional investors participated in the offering.
- Pharvaris intends to use the net proceeds from this offering primarily to fund research and development and product discovery expenses for its clinical and preclinical research and development activities and for working capital and general corporate purposes.
- This is Leerink Partners' 2nd bookrun offering for Pharvaris and 51st bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

MIAMI
1395 Brickell Avenue
Suite 800
Miami, FL 33131

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111